GP Pharm, S.A. - Product Pipeline Review - 2016

  • ID: 3960456
  • Company Profile
  • 22 pages
  • Global Markets Direct
1 of 5
GP Pharm, S.A. - Product Pipeline Review - 2016

The report ‘GP Pharm, S.A. - Product Pipeline Review - 2016’, provides an overview of the GP Pharm, S.A.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by GP Pharm, S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

- The report provides a snapshot of the pipeline therapeutic landscape of GP Pharm, S.A.
- The report provides overview of GP Pharm, S.A. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses GP Pharm, S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features GP Pharm, S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy:

- Evaluate GP Pharm, S.A.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for GP Pharm, S.A.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding GP Pharm, S.A.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

GP Pharm, S.A. Snapshot

GP Pharm, S.A. Overview

Key Facts

GP Pharm, S.A. - Research and Development Overview

Key Therapeutic Areas

GP Pharm, S.A. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

GP Pharm, S.A. - Pipeline Products Glance

GP Pharm, S.A. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

GP Pharm, S.A. - Drug Profiles

leuprolide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate MAR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pegylated Doxorubicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

risperidone depot - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GP Pharm, S.A. - Pipeline Analysis

GP Pharm, S.A. - Pipeline Products by Target

GP Pharm, S.A. - Pipeline Products by Route of Administration

GP Pharm, S.A. - Pipeline Products by Molecule Type

GP Pharm, S.A. - Pipeline Products by Mechanism of Action

GP Pharm, S.A. - Dormant Projects

GP Pharm, S.A. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

List of Tables

GP Pharm, S.A., Key Facts

GP Pharm, S.A. - Pipeline by Indication, 2016

GP Pharm, S.A. - Pipeline by Stage of Development, 2016

GP Pharm, S.A. - Monotherapy Products in Pipeline, 2016

GP Pharm, S.A. - Preclinical, 2016

GP Pharm, S.A. - Pipeline by Target, 2016

GP Pharm, S.A. - Pipeline by Route of Administration, 2016

GP Pharm, S.A. - Pipeline by Molecule Type, 2016

GP Pharm, S.A. - Pipeline Products by Mechanism of Action, 2016

GP Pharm, S.A. - Dormant Developmental Projects,2016

GP Pharm, S.A., Other Locations

List of Figures

GP Pharm, S.A. - Pipeline by Indication, 2016

GP Pharm, S.A. - Pipeline by Target, 2016

GP Pharm, S.A. - Pipeline by Route of Administration, 2016

GP Pharm, S.A. - Pipeline by Molecule Type, 2016

GP Pharm, S.A. - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Bristol-Myers Squibb Company
- ChemoCentryx, Inc.
- Ligand Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll